Populate, a management platform owned by mixed-use developer Socius, has appointed Dr Angela Kukula as Director of Science and Innovation. Dr Kukula was previously Chief Executive of MedCity and Director of Life Sciences at London & Partners, where she championed London’s life sciences sector on the global… Read More
R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2030 Strategy, setting out ambitious plans to translate scientific and technological innovation into better health outcomes. The regulator says that the commitments will enable it to keep pace with rapid advances in science, technology and personalised… Read More
Lundbeck has announced results from an open-label Phase Ib trial evaluating Lu AF28996, a novel, investigational, oral prodrug of D1-like/D2-like dopamine receptor agonist, in people with advanced Parkinson’s disease experiencing motor symptoms sub-optimally controlled despite optimised non-invasive antiparkinsonian medication. The results are being presented at the… Read More
Roche and Zealand Pharma have shared positive topline results from the Phase II ZUPREME-2 trial evaluating petrelintide versus placebo in people living with overweight or obesity and type 2 diabetes. The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week)… Read More
The pharmacological behaviour of drugs is determined not only by their intrinsic properties but also by the sensitivity of the biological systems in which they are evaluated. Variations in receptor density and signal transduction efficiency can significantly influence observed drug responses, complicating the translation of in vitro findings to in… Read More
The American Association of Pharmaceutical Scientists (AAPS) has announced details of its 2026 PharmSci 360 conference, including opening and closing plenary speakers, a collaboration with the United States Pharmacopeia (USP) and two Innovator-Curated tracks. The event will take place from October 25–28 at the Ernest N Morial Convention Center in… Read More
argenx has revealed that it will discontinue the Phase III UNITY study of Vyvgart Hytrulo (efgartigimod subcutaneous – efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren’s disease. The company said the decision is based on the recommendation from an Independent Data Monitoring Committee (IDMC) to stop… Read More
CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases. Under the terms of the agreement, Alentis will receive a… Read More
Scientists have uncovered a previously unknown mechanism that helps breast cancer cells survive the intense stresses of being malignant, revealing a promising new target for future cancer therapies. A new study has shown that breast cancer cells become highly dependent on a cell membrane protein called GPR89… Read More
The results of a new study show AI/ML investment jumping after three flat years, with three quarters (76%) of respondents planning to increase spending on technology in the next two years, up from 60% in 2023, 62% in 2024, and 63% in 2025. However, the leading barrier… Read More
Bio-Techne has opened a new manufacturing facility for Good Manufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom. The purpose-built 10,000-square-foot Bristol facility features five ISO-8 multifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small molecule manufacturing and product handling. Designed to meet the rigorous standards required for… Read More
Caribou Biosciences has announced that it is discontinuing its two allogeneic CAR-T cell therapy programmes due to financing constraints. It will discontinue development of vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. … Read More
Alector has granted Genentech worldwide rights to develop and commercialise its AL050 programme, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT). As part of the deal, Alector will receive a $100 million upfront payment, with potential for up to $1.17 billion in additional milestone payments, as… Read More
Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More
Rewind Therapeutics has announced additional financing to advance the development of its lead GPR17 antagonist programme, a potential disease modifying oral therapy intended to promote remyelination and restore neurological function in multiple sclerosis (MS). MS is characterised by damage to myelin, but there are no approved therapies… Read More
